High PSA but Normal Prostate MRI: Can Prostate Cancer Still Be Present?

This follows naturally from the first article and targets a very common patient question.

High PSA but Normal Prostate MRI: Can Prostate Cancer Still Be Present?

A common situation in prostate cancer evaluation is:

“My PSA is high, but my prostate MRI is normal. Does that mean I don't have prostate cancer?”

The answer is not necessarily.

A normal or non-suspicious multiparametric MRI (mpMRI) is reassuring because it significantly reduces the likelihood of clinically significant prostate cancer. However, MRI cannot completely rule out prostate cancer.

The decision about whether further investigation or prostate biopsy is required depends on the entire clinical picture—not MRI alone.

What Does a “Normal” Prostate MRI Mean?

Prostate MRI is usually reported using the PI-RADS (Prostate Imaging Reporting and Data System) scoring system.

Broadly:

• PI-RADS 1: Clinically significant prostate cancer is highly unlikely
• PI-RADS 2: Clinically significant prostate cancer is unlikely
• PI-RADS 3: Equivocal finding
• PI-RADS 4: Clinically significant cancer is likely
• PI-RADS 5: Clinically significant cancer is highly likely

When patients say their MRI is “normal,” they usually mean that the MRI has shown PI-RADS 1 or PI-RADS 2 findings, without a suspicious lesion requiring targeted biopsy.

This is reassuring—but it does not reduce the risk to zero.

How Reliable Is a Normal Prostate MRI?

Multiparametric MRI has transformed the diagnosis of prostate cancer because it can identify suspicious areas within the prostate before biopsy.

In the landmark PROMIS study, mpMRI had a negative predictive value of approximately 89% for clinically significant prostate cancer using the study's primary definition. This means that a negative MRI substantially lowers the probability of important cancer, but some clinically significant cancers can still be missed.

The exact residual risk varies according to the population studied, MRI quality, radiologist expertise and the definition of clinically significant cancer.

This is why MRI should be considered an important risk-stratification tool rather than an absolute cancer-exclusion test.

Why Can PSA Be High When MRI Is Normal?

There are several possibilities.

1. Benign Prostatic Enlargement

PSA is produced by prostate tissue—not exclusively by prostate cancer.

A man with a very large benign prostate may therefore have a raised PSA despite having no suspicious lesion on MRI.

This is where PSA density becomes particularly useful.

2. Prostatitis or Inflammation

Inflammation of the prostate can increase PSA.

Urinary infection, acute prostatitis and other inflammatory conditions can occasionally produce considerable PSA elevations.

3. Recent Urinary Retention or Instrumentation

Acute urinary retention and certain procedures involving the urinary tract or prostate can temporarily elevate PSA.

The timing and clinical circumstances surrounding the PSA test therefore matter.

4. MRI-Occult Prostate Cancer

Some prostate cancers are simply difficult to visualise on MRI.

Small lesions, certain tumour locations and some histological patterns may be less conspicuous. MRI quality and interpretation also influence diagnostic performance.

Therefore:

Normal MRI ≠ zero possibility of prostate cancer.

PSA Density Becomes Particularly Important

One of the most useful parameters when PSA is elevated but MRI is negative is PSA density (PSAD).

It is calculated as:

PSA Density = Serum PSA ÷ Prostate Volume

For example:

A man with a PSA of 8 ng/mL and prostate volume of 80 mL has:

PSA density = 8 ÷ 80 = 0.10 ng/mL/cc

Another man with the same PSA of 8 ng/mL but a prostate volume of only 30 mL has:

PSA density = 8 ÷ 30 = 0.27 ng/mL/cc

Both men have exactly the same PSA, but their risk profiles are quite different.

This illustrates why PSA should not be interpreted in isolation.

Does a Normal MRI Mean I Can Avoid Prostate Biopsy?

Sometimes—but not always.

Current diagnostic strategies allow biopsy to be omitted in appropriately selected men with a negative MRI and sufficiently low clinical suspicion, provided that appropriate follow-up is arranged.

However, biopsy may still be considered despite a negative MRI when other features remain concerning, such as:

• Persistently elevated or rising PSA
• High PSA density
• Abnormal digital rectal examination
• Strong family history of prostate cancer
• Other recognised inherited risk factors
• Significant clinical suspicion despite imaging
• Previous concerning biopsy or pathological findings

Therefore, the question should not simply be:

“Is my MRI normal?”

It should be:

“After considering my MRI, PSA density, examination and other risk factors, is my remaining risk low enough to safely avoid biopsy?”

What If PSA Continues to Rise After a Normal MRI?

A rising PSA after a negative MRI deserves reassessment rather than automatic reassurance or automatic biopsy.

The clinician may review:

Was the original PSA reliable?

Potential reversible causes of PSA elevation should be considered.

What is the prostate volume and PSA density?

A disproportionately high PSA relative to prostate size may increase suspicion.

Was the MRI technically adequate?

High-quality acquisition and interpretation by radiologists experienced in prostate MRI matter.

Has the clinical risk changed?

A persistent or increasing PSA, abnormal examination or other risk factors may justify repeat imaging or biopsy.

The appropriate approach depends on the individual patient.

Should Antibiotics Be Given Just to Reduce PSA?

Routine empirical antibiotics simply because PSA is elevated are generally not appropriate in an asymptomatic man without evidence of bacterial infection.

A temporary fall in PSA following antibiotics also does not reliably prove that prostate cancer is absent.

Antibiotics should therefore be used when there is an appropriate clinical indication rather than simply as a “PSA-lowering test.”

Can a PI-RADS 2 MRI Still Have Cancer?

Yes.

PI-RADS 2 means that clinically significant cancer is considered unlikely on MRI, not impossible.

This distinction is important.

The probability of significant cancer after a PI-RADS 1–2 MRI depends considerably on the patient's underlying risk. A patient with a modest PSA elevation, large benign prostate, low PSA density and normal examination is very different from a patient with persistently high PSA, small prostate and high PSA density.

What Happens Next After a High PSA and Normal MRI?

There is no single pathway suitable for everyone.

Depending on the risk profile, the next step may be:

• PSA surveillance
• Repeat PSA after an appropriate interval
• Calculation of PSA density
• Clinical examination
• Review of MRI quality/images
• Repeat MRI in selected circumstances
• Additional risk assessment where appropriate
• Prostate biopsy when residual suspicion remains significant

The aim is to avoid both unnecessary biopsies and missed clinically significant prostate cancers.

The Take-Home Message

A normal prostate MRI is reassuring, but it is not a 100% guarantee that prostate cancer is absent.

If PSA remains elevated despite a PI-RADS 1 or 2 MRI, the result should be interpreted together with prostate volume, PSA density, PSA trend, examination findings, family history and overall clinical risk.

For some men, careful PSA surveillance may be entirely appropriate. For others, a prostate biopsy may still be necessary despite a normal MRI.

The important question is therefore not:

“My MRI is normal—so am I safe?”

but:

“What is my remaining risk of clinically significant prostate cancer after taking all the available information into account?”

Dr. Anshuman Singh

M.S., M.Ch. Urology (Gold Medalist)

Fellowship - Uro-Oncology & Robotic Surgery (USI, Intuitive certified)

Visiting Fellow - Robotic Uro-Oncology (Fundacio Puigvert, Spain)
Clinical Observer - Robotic Pelvic Oncology (University College Hospitals, London)

Vice Chairperson - Uro-Oncology & Robotic Surgery

Chandan Cancer Institute, Chandan Hospital

Lucknow

Uro-Onco Connect – Advanced Uro-Oncology & Robotic Surgery

References

1. Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS). Lancet. 2017;389:815–822.
2. Kasivisvanathan V, Rannikko AS, Borghi M, et al. MRI-targeted or standard biopsy for prostate-cancer diagnosis (PRECISION). N Engl J Med. 2018;378:1767–1777.
3. European Association of Urology. Guidelines on Prostate Cancer: Diagnostic Evaluation. 2026.
4. Turkbey B, Rosenkrantz AB, Haider MA, et al. Prostate Imaging Reporting and Data System Version 2.1. Eur Urol. 2019;76:340–351.